id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-2596-0006,FDA,FDA-2018-E-2596,Patent Term Extension Letter from FDA CDER to U S Patent Trademark Office,Other,Letter(s),2020-07-27T04:00:00Z,2020,7,2020-07-28T04:00:00Z,,2020-07-28T16:20:06Z,,0,0,09000064847acef3
FDA-2018-E-2596-0005,FDA,FDA-2018-E-2596,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-06-22T04:00:00Z,2020,6,2020-06-22T04:00:00Z,,2020-06-22T18:20:00Z,,0,0,09000064846ff1cb
FDA-2018-E-2596-0004,FDA,FDA-2018-E-2596,Determination of Regulatory Review Period for Purposes of Patent Extension; LUXTURNA,Notice,Determinations,2019-12-05T05:00:00Z,2019,12,2019-12-05T05:00:00Z,2020-06-03T03:59:59Z,2019-12-05T14:47:45Z,2019-26252,0,0,09000064841e7408
FDA-2018-E-2596-0003,FDA,FDA-2018-E-2596,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T20:41:15Z,,0,0,0900006484116d4b
FDA-2018-E-2596-0002,FDA,FDA-2018-E-2596,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T18:41:39Z,,0,0,0900006483c72eaa
FDA-2018-E-2596-0001,FDA,FDA-2018-E-2596,Letter from U S Patent and Trademark Office,Other,Letter(s),2018-07-05T04:00:00Z,2018,7,2018-07-05T04:00:00Z,,2018-07-05T19:03:38Z,,0,0,09000064834afc38